Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine

SHANGHAI, CHINA, May 13, 2022 – (ACN Newswire) – Hua Medicine (the "Company", stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin, a glucokinase activator (GKA) and first-in-class investigational drug of the Company for the treatment of diabetes, were published online simultaneously by Nature Medicine, an international top medical journal. These two papers described and analyzed the clinical efficacy and safety characteristics of dorzagliatin monotherapy (SEED) in drug-naive Type 2 diabetes (T2D) patients and the combination therapy of dorzagliatin and metformin (DAWN) in patients who failed in metformin adequacy therapy for the treatment of T2D respectively.




It was the first time for Nature Medicine to publish the results of Phase III trials of a GKA, representing the results of large registered clinical studies in China. Dorzagliatin is a new first-in-class GKA antidiabetic drug to successfully complete the Phase III registered clinical study in the world, which was led by Chinese researchers. The two papers are also the first to be published in Nature Medicine with Chinese researchers as the first and corresponding authors of a novel mechanism for treatment of diabetes. Both studies demonstrated that by addressing the defect of the glucose sensor function of glucokinase (GK), dorzagliatin is able to continuously and effectively reduce HbA1c in patients with T2D, and significantly reduce post-meal glucose (2h-PPG) during the treatment period. The percentage of patients admninistered dorzagliatin achieving standard glycemic blood glucose control was demonstrated to be high and with low hypoglycemia incidences. It was also shown that dorzagliatin has good safety and tolerability. In addition, it can continuously improve beta-cell function and reduce insulin resistance.

Dorzagliatin is the first-in-class oral drug developed by Hua Medicine for the treatment of T2D after 10 years of independent research and development, which identifies GK as a therapeutic target. GK plays a critical role in maintaining blood glucose homeostasis in human body, serving as a glucose sensor to sense changes of the blood glucose, and timely stimulates glucose control organs to secrete insulin, GLP-1 or glucagon, so as to effectively regulate blood glucose level and maintain blood glucose homeostasis (4-6.5 mmol/L). Impaired sensitivity of glucose, mainly manifested as impaired glucose stimulated insulin secretion (GSIS) function of pancreatic beta-cells and rise of FPG level blood sugar fluctuations, is the root cause of T2D. Dorzagliatin can act on GK in glucose control organs such as pancreas, liver and intestine. By restoring GK activity in T2D patients, it helps restore the sensitivity of the human body to blood glucose changes, and thus improves the early phase insulin secretion and beta-cell function. In this way, blood glucose homeostasis can be rebuilt to control or delay the progression of T2D, and fundamentally treat diabetes and discontinue medication. Hua Medicine has published over 10 papers on the results of basic and clinical studies to continually elaborate its scientific concept of "restoring sensitivity, rebuilding homeostasis, and treating diabetes at its source". The results of the Phase III trial published by Nature Medicine are the clinical validation of this innovative concept. In March 2021, Hua Medicine submitted the new drug application (NDA) of dorzagliatin to the China National Medical Products Administration (NMPA) for T2D treatment, which was accepted in April. Currently, the NDA of dorzagliatin is under active review by the NMPA. Hua Medicine is fully supporting this process to obtain the approval of dorzagliatin as early as possible.

Nature Medicine is a top journal, focusing on the field of biomedicine. It mainly publishes original research papers that "demonstrate novel insight into disease processes, with direct evidence of the physiological relevance of the results", and has begun to focus on publishing papers of large clinical research in recent years. The impact factor of Nature Medicine has been on the rise. With a 2-year impact factor of 53.44, it has surpassed Nature to be one of the top five medical journals, also including The New England Journal of Medicine (NEJM), The Lancet, The Journal of the American Medical Association (JAMA) and The British Medical Journal (BMJ), known traditionally as four medical journals. Since 2009, Franz Matschinsky, the father of GK, first reported the research and development of GKA in Nature Reviews Drug Discovery, the theoretical research and drug research and development results related to GKA have drawn worldwide attention, and have been highly valued by the international academic and clinical medical communities. Before, the results of the Phase II clinical trial of dorzagliatin were published in the advanced medical journal The Lancet Diabetes and Endocrinology. Since 2014, Hua Medicine has been presenting the results of basic researches and clinical studies of dorzagliatin at the world's largest and most important diabetes conference – the American Diabetes Association (ADA) Scientific Sessions every year. It was through the ADA Scientific Sessions that the editors of Nature Medicine noticed the innovativeness and breakthrough nature of dorzagliatin, and took the initiative to make an appointment with Hua Medicine for scripts. These two newly published papers present the Phase III results of the SEED study and the DAWN study of dorzagliatin, respectively.

The SEED study is a study of dorzagliatin monotherapy. It is a randomized, double-blind and placebo-controlled Phase III registered clinical study in drug naive T2D patients. The study was conducted among 463 T2D patients. The first 24 weeks were randomized, double-blind and placebo-controlled treatment, designed to evaluate the primary efficacy and safety endpoints of dorzagliatin. The subsequent 28 weeks were open-label period for dorzagliatin, designed to continuously observe and evaluate the safety of dorzagliatin. The SEED study was led by Professor Dalong Zhu, the President of the Chinese Diabetes Society, and Director of Medical Center for Endocrine and Metabolic Diseases of Gulou Hospital, affiliated to Medical College of Nanjing University. This study showed that dorzagliatin can effectively reduce the blood glucose of drug naive T2D patients, with good safety and tolerability. The main conclusions of the SEED study include:

Significant and long-lasting efficacy:
— There was a 1.07% HbA1c reduction from baseline in 24 weeks, significantly better than that of the placebo treated group (p<0.001)
— The standard-reaching rate of HbA1c was 42.5% in 24 weeks, significantly higher than that of the placebo treated group (p<0.001)
— Significantly improved beta cell function, with a 3.28 increase in HOMA2-beta in 24 weeks compared with the placebo treated group
— The 2h-PPG observably decreased by 2.33mmol/L compared with the placebo treated group in 24 weeks
— The FPG observably decreased by 0.33mmol/L compared with the placebo treated group in 24 weeks
— The HbA1c continued to remain steady in 52 weeks

Good tolerability and safety:
— The hypoglycemia (<3mmol/L) incidence rate was less than 1% in 24 weeks, and there was no severe hypoglycemia reported
— The hypoglycemia (<3mmol/L) incidence rate was less than 1% in 52 weeks, and there was no severe hypoglycemia reported
— In 52 weeks, there was no drug-related SAE

The DAWN study is a randomized, double-blind, placebo-controlled Phase III study among 767 patients, which uses dorzagliatin combined with metformin to treat T2D patients who failed in metformin adequacy therapy. The first 24 weeks were randomized, double-blind and placebo-controlled treatment, designed to evaluate the primary efficacy and safety endpoints of dorzagliatin. The subsequent 28 weeks were open-label period for dorzagliatin, designed to continuously observe and evaluate the safety of dorzagliatin. The DAWN study was led by Professor Wenying Yang at China-Japan Friendship Hospital, who is the former President of the Chinese Diabetes Society and present Vice President of the Asian Diabetes Association. This study showed that dorzagliatin can effectively reduce the blood glucose of T2D patients who failed in metformin adequacy therapy, with good safety and tolerability. The main conclusions of the DAWN study include:

Significant and long-lasting efficacy:
— The HbA1c reduction was 1.02% from baseline, significantly better than that of the placebo treated group in 24 weeks
— The standard-reaching rate of HbA1c was 44.4% in 24 weeks, significantly higher than 10.7%(p<0.0001) in the placebo treated group
— Significantly improved beta cell function and HOMA2-beta increased by 2.43 compared with the placebo treated group in 24 weeks
— The 2h-PPG observably decreased by 2.48mmol/L compared with the placebo treated group in 24 weeks
— The FPG observably decreased by 0.38mmol/L compared with the placebo treated group in 24 weeks
— The HbA1c continued to remain steady in 52 weeks

Good tolerability and safety:
— The hypoglycemia (<3mmol/L) incidence rate is less than 1% in 24 weeks, and there was no severe hypoglycemia reported
— The hypoglycemia (<3mmol/L) incidence was less than 1% in 52 weeks, and there was no severe hypoglycemia reported
— In 52 weeks, there was no drug-related SAE

Professor Dalong Zhu, the first author of the paper on SEED, said, "The investigator team of dorzagliatin and the R&D team of Hua Medicine have always focused on the clinical needs of patients and adhered to scientific rigor to successfully develop this first-in-class new drug together. The publication of the results of the two Phase III clinical studies on Nature Medicine is another proof of the international academic community recognizing China's new drug development capabilities. As a clinical investigator, I feel very proud and confident about the future of innovative drug development in China. In clinical trials, dorzagliatin has demonstrated long-lasting and stable efficacy, as well as good safety and tolerability. In the meanwhile, it showed significant potentiation in combination trials with SGLT-2 inhibitors and DPP-4 inhibitors. I am very much looking forward to bringing new treatment options with dorzagliatin to Chinese T2D patients soon."

Professor Xiaoying Li, the co-corresponding author of the paper and Director of the Department of Endocrinology at Zhongshan Hospital affiliated to Fudan University, said, "Nature Medicine is a top journal with a high impact factor. The clinical trial of dorzagliatin is designed in line with the standards of international multinational companies. All the investigators and developers followed a high bar of standards and quality, which led to the creation of such a high-value breakthrough drug. I'm very proud and excited about this achievement. Type 2 diabetes is a critical threat to human health. As clinicians, our involvement in the clinical development of dorzagliatin has given us the opportunity to review the regulating mechanisms of glucose homeostasis and to better understand the process and characteristics of the progression of type 2 diabetes. "

Professor Wenying Yang, the first author of the DAWN paper, said, "I am very excited and happy! Before, the results of Phase II clinical study of dorzagliatin were published in The Lancet Diabetes and Endocrinology, and now the results of Phase III clinical study were published in Nature Medicine. Such achievements are completely on par with the first-in-class diabetes drugs developed by multinational pharmaceutical companies. This is a great recognition on Chinese innovative drugs, the best return to Hua Medicine and Dr. Chen Li's 10 years of hard work, and the most memorable experience for us as clinical investigators. We are fortunate to meet such a good pioneer. I look forward to the launch of dorzagliatin soon!"

Dr. Yi Zhang, Chief Medical Officer, Senior Vice President of Pharma Development of Hua Medicine and the head of clinical development for dorzagliatin, said, "The publication of the results of the two clinical studies, i.e., the SEED study and the DAWN study, on Nature Medicine fully demonstrated the scientific research capabilities of Chinese clinical researchers and Hua Medicine's innovative R&D strengths as a China-based biopharmaceutical company. The Phase III clinical trial of dorzagliatin is the first confirmatory clinical study of GKA drugs completed worldwide. It is also the first clinical trial of a first-in-class investigational diabetes drug led by a Chinese clinical team with Chinese subjects as the research objects. We are very grateful to all clinical researchers for their unremitting efforts and hard work. In the future, Hua Medicine is confident to join hands with partners in various clinical fields to make new breakthroughs in the field of Type 2 diabetes and the whole metabolic diseases."

Dr. Li Chen, Founder, CEO, Chief Scientific Officer of Hua Medicine and corresponding author of both papers, said, "We are very pleased to collaborate with Jennifer Sargent, Editor-in-Chief, to publish the clinical research results of dorzagliatin in Nature Medicine. This illustrates the strong interest and attention of the international medical community on the GK mechanism and GKA drugs. In 1968, Professor Franz Matschinsky, the father of glucokinase, discovered the critical role of GK in glucose-stimulated insulin secretion and proposed glucokinase as a diabetes gene and glucose sensor. The drug development of glucokinase activators has, since then, undergone numerous difficulties and failures. More than 50 years later, I am very pleased to see that Hua Medicine R&D team and Chinese clinical experts, after ten years of hard work, have overcome many R&D difficulties and greatly improved the understanding of glucokinase's role in the regulation of blood glucose homeostasis and diabetes treatment, established the world's leading scientific concept of diabetes treatment, and successfully transformed it into the breakthrough new drug dorzagliatin. The recently results of the DREAM study, further elucidates that dorzagliatin can fundamentally treat T2D and achieve diabetes remission without any glucose-lowering medication after the completion of the SEED study. Hua Medicine is proactively supporting the NMPA approval process to bring this innovative drug to the benefit of Chinese type 2 diabetes patients as soon as possible."

Design of the SEED study
The SEED study is a randomized, double-blind and placebo-controlled Phase III study conducted in 463 drug naive T2D patients. The whole study lasted for 53 weeks, including 52 weeks of treatment and 1 week of safety follow-up. The first 24 weeks were randomized, double-blind and placebo-controlled to assess the efficacy and safety of dorzagliatin. Patients were treated with twice-daily doses of dorzagliatin (75mg) or placebo, randomized 2:1. The subsequent 28-week were the open-label treatment period, during which all subjects were treated with twice-daily doses of dorzagliatin (75mg). The study was conducted at 40 clinical sites across China led by Professor Dalong Zhu, the President of the Chinese Diabetes Society, Director of Medical Center for Endocrine and Metabolic Diseases of Gulou Hospital, affiliated to Medical College of Nanjing University. (Clinical study registration number: NCT03173391)

Design of the DAWN study
The DAWN study is a randomized, double-blind, placebo-controlled Phase III study in 767 Type 2 diabetes patients, which uses dorzagliatin combined with metformin to treat patients who failed in metformin adequacy therapy. During the first 24 weeks of double-blinded treatment, subjects were treated with metformin (Glucophage) at 1,500mg/day as the basic therapy, and they were given twice-daily doses of dorzagliatin (75mg) or placebo, randomized on a 1:1 ratio. During the subsequent 28-week open-label treatment period, all subjects received dorzagliatin 75mg twice daily and 1500mg/day of metformin (Glucophage). The trial was conducted in 72 clinical sites across China led by Professor Wenying Yang of China-Japan Friendship Hospital, the former President of the Chinese Diabetes Society and present Vice President of the Asian Diabetes Association. (Clinical study registration number: NCT03141073)

About Dorzagliatin
Dorzagliatin is an investigational first-in-class, dual-acting glucokinase activator, designed to control the progressive and degenerative nature of diabetes by restoring glucose homeostasis in patients with Type 2 diabetes. By fixing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired insulin and GLP-1 secretion of patients with Type 2 diabetes and serve as a cornerstone therapy targeting the root cause of the disease. Two Phase III registered trials for dorzagliatin monotherapy and the combination of dorzagliatin and metformin respectively have been completed in China, as well as the studies on drug mechanism synergy with sitagliptin (DPP-4 inhibitor) and empagliflozin (SGLT-2 inhibitor). In an investigator-initiated study named as DREAM, a 65.2% diabetes remission rate was observed without any antidiabetes medication during the 52-week study period. The Company has obtained the "Drug Manufacturing Permit" of dorzagliatin issued by the Shanghai Municipal Drug Administrative Bureau, and has submitted its NDA to the National Medical Products Administration in order to realize the "First in Global, Start from China" mission for the benefits of diabetic patients worldwide.

About Hua Medicine

Hua Medicine is an innovative drug development company in China focused on developing novel therapies for patients worldwide with unmet medical needs. Hua Medicine teams up with global high caliber people and integrates global resources to explore breakthrough technologies and products and accelerate global innovation in diabetes care. Targeting the glucose sensor glucokinase, dorzagliatin, a novel oral diabetes drug restoring glucose sensitivity in T2D patients, has completed SEED and DAWN registration trials, and filed NDA in China. This global first-in-class glucokinase activator (GKA) has demonstrated its potential of achieving diabetes remission to help millions of diabetic patients around the world.

For more information
Hua Medicine
Website: www.huamedicine.com

Investors
Email: ir@huamedicine.com

Media
Email: pr@huamedicine.com


Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Q&M Dental net profit, excluding other gains or losses, increased by 25% to S$7.2 million on S$46.8 million of revenue for quarter ended 31 March 2022

SINGAPORE, May 12, 2022 – (ACN Newswire) – Q&M Dental Group (Singapore) Limited, a leading private dental healthcare group in Asia, reported net profit excluding other gains or losses attributable to shareholders of S$7.2 million for the quarter ended 31 March 2022 (1Q2022) compared to S$5.8 million in the corresponding period (1Q2021).



Dr Ng Chin Siau, Chief Executive Officer of Q&M Dental said, "We are heartened by our continuous strong performance in 1Q2022 following a record-setting year FY2021. Our core dental business will remain strong, and with the abolishing of most of the pandemic restrictions, a positive impact on the economy, we are looking forward to resuming our growth trajectory of expanding our network of clinics in the coming quarters."

Growth & Expansion in Operations

As at 31 March 2022, the Group's number of dental outlets in Singapore has grown to 99, from 85 as at 31 March 2021. Similarly in Malaysia, the number of dental outlets has increased to 41, as compared to 36 previously.

The Group also continues to focus on its expansion into medical diagnostics, with its associated Company, Aoxin Q&M Dental Group Limited and through its recent acquisition of 49% shareholding of Acumen Diagnostics Pte. Ltd., raising Q&M's effective interest in Acumen Diagnostics from 51% to 67%. In the near term, Acumen Diagnostics' clinical testing laboratory will roll out its pipeline of new tests, including PCR assays for dengue, sepsis and, identification of bacterial pathogens and their associated antibiotics resistance in pneumonia and bloodstream infections. Its longer-term plans include the development of new vaccines.

For 1Q2022, revenue contribution from dental and medical clinics was relatively unchanged with a marginal decrease of 2% to S$38.6 million, despite the challenges of the tightening of Safe Management Measures (SMM) due to the rapid spread of the Omicron variant. Revenue contribution from medical laboratory and dental equipment & supplies segment surged by 80% to S$8.2 million on the back of increased revenue from Covid-19 testing from Acumen Diagnostics, the Group's medical laboratory business, which obtained its medical laboratory license in September 2020.

The Group's net profit after tax excluding other gains or losses for 1Q2022 increased by 25% to S$7.2 million, from S$5.8 million in the corresponding period last year, translating to an earnings per share of 0.69 Singapore cent.

As at 31 March 2022, the Group had cash and cash equivalents of S$43.5 million with net assets of S$94.9 million. This translates to Net Asset Value per share of 10.10 cents per share.

Outlook & Further Expansion Plans

With the opening up of the Singapore economy gathering pace in 2022, the country expects to see businesses ramping up in most sectors with those that were most severely affected by the pandemic like F&B, tourism to especially benefit. The government is forecasting GDP growth of between 3.0 to 5.0% in 2022, Barring any major changes in the global macroeconomic and political situation or any new adverse developments in the evolving Covid-19 situation, the Group is cautiously optimistic on its business outlook.
The Group intends to continue executing the business plans outlined below:

– Expansion of network of dental clinics in Singapore and Malaysia

The Group currently operates 99 clinics in Singapore. With the economy opening up in 2022, the Group will also intensively increase its reach through organic growth of its dental clinic network in Singapore. This will be supported by an expansion of its team of dentists to undergird the future growth of its operations in Singapore. We will continue to develop, invest and optimise our digital Artificial Intelligence (AI) guided clinical decision support system to provide the most effective and suitable treatment plans for patients. The Group believes it is well-positioned to cater to the rising demand for primary and high-value specialist dental healthcare services of its patients.

Currently, the Group operates 41 clinics in Malaysia. The clinics are located in Johor (16 dental clinics), Kuala Lumpur (9 dental clinics), Selangor (11 dental clinics), Melaka (4 dental clinics) and 1 dental clinic in Negeri Sembilan.

The Group intends to open at least 30 dental clinics a year from 2021 onwards in Singapore and Malaysia for the next 10 years. The eventual number of dental outlets will depend on available opportunities, pertinent market conditions and the evolving Covid-19 situation.

– Expansion into private dental healthcare market in the People's Republic of China ("PRC")

The main thrust of the Group's proposed expansion in PRC is through organic growth to develop a new and sustainable growth pillar that can yield long term value for the Group.

– Expansion in Southeast Asia

The Group is continuously looking out for strategic opportunities to expand its dental business and regional footprint to other Southeast Asian countries.

– Medical Laboratory

The Group will focus on rolling out its clinical testing laboratory pipeline of new tests including PCR assays for dengue sepsis and identification of bacterial pathogens and their associated antibiotics resistance in pneumonia and bloodstream infections.

Please see links for PDF documents from SGXNET.
Results: https://tinyurl.com/QnM-1Q2022-Result
Press Release: https://tinyurl.com/QnM-1Q-2022-Release

About Q&M Dental Group (Singapore) Limited (QC7.SI)

Q&M Dental Group (Singapore) Limited (QC7.SI) ("Q&M" or together with its subsidiaries, the "Group") is a leading private dental healthcare group in Asia.

The Group owns the largest network of private dental outlets in Singapore, operating 99 dental outlets across the country. Underpinned by about 290 experienced dentists and over 350 supporting staff, the Group sees an average of 40,000 patient visits a month in Singapore. The Group also operates 5 medical clinics and a dental supplies and equipment distribution company.

Outside of Singapore, the Group has 41 dental clinics and a dental supplies and equipment distribution company in Malaysia, as well as a dental clinic in the People's Republic of China ("PRC"). Q&M is also the substantial shareholder of Aoxin Q&M Dental Group Limited, a dental Group listed on the Catalist board of the Singapore Exchange that operates dental clinics and hospitals primarily in the north- eastern region of the PRC. The Group aims to expand its operations geographically and vertically through the value chain in Malaysia, the PRC and within the ASEAN region.

The Q&M College of Dentistry was established in 2019 to offer postgraduate dental education as part of its commitment to continual education and professional development of dentists. It offers Singapore's first private postgraduate diploma programme in clinical dentistry.

In 2020, the Group expanded into the medical laboratories and research industry with the strategic investment into Acumen Diagnostics Pte. Ltd. ("Acumen"). Acumen currently focuses on the manufacture, sale and distribution of COVID-19 diagnostic test kits, as well as COVID-19 testing. It is also working to roll out a pipeline of new tests, including PCR assays for dengue, sepsis and, identification of bacterial pathogens and their associated antibiotics resistance in pneumonia and bloodstream infections.

EM2AI Pte Ltd, a wholly-owned subsidiary of the Group that focuses on developing AI-powered solutions to diagnosis and treatment planning has rolled out IDMS, enabling dentists within the Group's network to administer ethical treatment plans for patients.

The Group was listed on the Mainboard of the Singapore Exchange Securities Trading Limited ("SGX- ST") on 26 November 2009. For more information on the Group, please visit www.QandMDental.com.sg

For more information, please contact:
Waterbrooks Consultants Pte Ltd
Wayne Koo
Tel: +65 9338-8166
Email: wayne.koo@waterbrooks.com.sg

Derek Yeo
Tel: +65 9791-4707
Email: derek@waterbrooks.com.sg

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Novotech Sponsors Pre-ASCO China Summit: Go/No Go Decisions Based on Early Phase Oncology Trials

SYDNEY, May 12, 2022 – (ACN Newswire) – Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its CRO services to the US, is pleased to sponsor the Pre-ASCO China Summit 2022 event titled: Go/No Go Decisions Based on Early Phase Oncology Trials ('The Summit').

The Summit will feature insights from leading Novotech experts tapping decades of oncology clinical experience in the APAC region. They include:
– Dr. Ramandeep Sharma, Senior Medical Monitor, Novotech
– Dr. Vivian Gu, Head of Clinical Development & Regulatory, CMO, Novotech China

Register here: https://www.eventbrite.com/e/pre-asco-china-2-gono-go-decisions-based-on-early-phase-oncology-trials-tickets-330427145487

Event Date:
– China Time: 9:00-10:30 AM, Saturday, May 14, 2022
– US EST Time: 9:00-10:30 PM, Friday, May 13, 2022
– US PST Time: 6:00-7:30 PM, Friday, May 13, 2022
Language: English, with Chinese simultaneous translation
Venue: Live Zoom Webinar
Moderator:
– Dr. Li Yan, CMO, Brii Biosciences; Managing Director, United States Chinese Anti-Cancer Association (USCACA)

The Summit will start with a presentation by Novotech's Senior Medical Monitor Dr. Ramandeep Sharma titled: Approaches, Experiences, and considerations for early phase go/no go.

A panel discussion will follow featuring leading clinical specialists including:
– Dr. Jin Li, Shanghai East Hospital
– Dr. Li Yan, CMO, Brii Biosciences; Managing Director, USCACA
– Dr. Ramandeep Sharma, Senior Medical Monitor, Novotech
– Dr. Vivian Gu, Head of Clinical Development & Regulatory, CMO, Novotech China
– Dr. Xiaoxia Yan, Highthink
– Dr. Jianmin Fang, Co-founder, CEO & CSO, RemeGen
– Dr. Joseph Eid, Chief Medical Officer, Hengrui
– Dr. Jon Wigginton, Senior Advisor and Chairman SAB, Cullinan Oncology; Former Head of Immuno-Oncology Early Clinical Development, BMS

Earlier this month, Novotech announced the acquisition of US CRO, NCGS as part of a US service expansion program for its global base of clients.

Novotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, can now offer its biotech clients clinical services in the US to support later phase global studies.

NCGS was established in 1984 in South Carolina with a biopharma client base. NCGS has a workforce of about 300 professionals across the US.

Novotech CEO Dr. John Moller said:

"This is a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs."

"Clients will receive seamless service, with a unified approach to systems and SOPs well developed," Moller said.

Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.

With more than 2,000 highly experienced professionals, clients benefit from strong site and Key Opinion Leader relationships, deep regulatory expertise, and the ability to accelerate clinical trials across the Asia Pacific and in particular China.

Novotech recently announced a partnership and investment in tech firm Prospection to support accelerated clinical trials with healthcare data analytics using real-world data.

Novotech has also partnered with virtual research organisation ObvioHealth to expedite trials leveraging remote technologies. This patient-centric approach improves subject retention and allows sponsors to reach populations outside major cities for clinical trial participation.

About Novotech Health Holdings

Novotech Health Holdings Pte. Ltd. ("Novotech") is a leading Asia-Pacific biotech specialist CRO and consists of two operating brands, Novotech and PPC. Novotech is a CRO with integrated labs and phase I facilities providing drug development consulting and clinical development services. It has been instrumental in the success of approximately 3,700 clinical trials across all trial phases and broad range of therapeutic areas. Novotech is well positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally. For more information visit https://novotech-cro.com/contact

Media Contact
David James
communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Elevating Australia’s Scientific Acumen: Large Molecule Facility Doubles Size of Australia’s Top Bioanalytical Laboratory

Thebarton, Australia, May 12, 2022 – (ACN Newswire) – Agilex Biolabs Pty Ltd has unveiled its new building with a ribbon cutting ceremony by The Honourable Stephen Patterson MP Minister for Trade and Investment at 12:30pm on Thursday 17 February 2022 at 31 Dalgleish street Thebarton South Australia 5031.

Agilex Biolabs launched its new laboratory for the analysis of large molecule therapeutics, more than doubling the geographic area of its Adelaide campus. The addition of this 2,520 m2 facility expands the service capabilities of Australia’s most technologically advanced bioanalytical partner and brings a new point of pride to South Australia.

State-of-the-art instrument platforms and increased capacity empower drug sponsors from all over the world to succeed as they expand into the novel, promising world of large molecule therapeutics. Areas of medicine such as oncology are seeing new ways of approaching treatment due to innovative modalities like antibody-drug conjugates (ADCs) and allogeneic cell therapies. Gene therapies and vaccines created using genetic platforms such as RNA, miRNA, and siRNA need specialised tools and technology to measure critical safety and efficacy endpoints in human clinical trials. The new Agilex large molecule facility features cutting-edge bioanalytical techniques and equipment specifically designed for these fast-growing therapeutic areas, such as digital droplet quantitative RT-PCR analysis and an EliSPOT/FluoroSPOT multi-spot reader for high-sensitivity molecule detection.

Before the new Agilex large molecule facility was built, many drug sponsors conducting clinical trials in Australia would have to ship their clinical samples to labs in other countries to get important patient safety data. The expansion into this kind of support represents South Australia’s ability and willingness to accommodate the huge influx of biopharmaceutical companies from all over the world bringing their toxicology studies and clinical programs to Australia.

Adelaide’s scientific community can blossom as Agilex Biolab continues to grow. Already staffed with over 150 scientists and support personnel, the comprehensive bioanalytical service headquarters will soon reach 200 welcoming experts from all over the world to its ranks.

“The world’s most talented, driven scientists are drawn to research facilities that foster scientific advancement and cutting-edge technology—many of those people will now be coming to Adelaide,” said Agilex Biolabs CEO, Jason Valentine. “Committed investment and our local community’s support for this new center of scientific excellence will elevate South Australia’s reputation for spurring innovation and harboring success.”

The community offered their enthusiastic applause at the new facility’s official opening on Thursday afternoon. The ribbon cutting ceremony was conducted by the Minister for Trade and Investment, The Honourable Stephen Patterson MP.

Minister for Trade and Investment Stephen Patterson said the State Government had an ambitious plan to grow SA’s Health and Medical Industries sector’s contribution to the state’s economy.

“As a government, we’re working collaboratively with industry to more than double the HMI economic contribution to SA from $2.3 billion to $5 billion by 2030.

“South Australia is open for business and at the forefront of world-leading capabilities, bio-tech precincts and an academic research ecosystem that makes it the ideal place to invest and do business.”

The traditional ‘welcome to country’ and cleansing ceremony was led by local indigenous leader Jack Buckskin.

About Agilex Biolabs

Agilex Biolabs is Australia’s leading provider of bioanalytical services and toxicology studies supporting preclinical and clinical drug development. With over 25 years of specialized experience and a rapidly growing suite of full-service offerings, Agilex equips biopharma companies from United States, Asia-Pacific, and European regions with reliable, defendable data as they advance novel therapeutics through the development pipeline. By combining specialized expertise, technological innovation, and a 25-year track record, the Agilex team has successfully supported hundreds of preclinical and clinical trials from around the world. Agilex Biolabs is headquartered in Adelaide, South Australia, with additional laboratory sites in Queensland. For more information, visit https://www.agilexbiolabs.com/

Social Links
Twitter: https://twitter.com/AgilexBiolabs
LinkedIn: https://linkedin.com/agilex-biolabs
YouTube: https://www.youtube.com/channel/UCK8yK3JxXni6QhiorMUIyLA

Media Contact
Janki Patel, Marketing Associate, Agilex Biolabs
E-Mail: janki.patel@agilexbiolabs.com
Website: https://www.agilexbiolabs.com/

SOURCE: Agilex Biolabs



Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Novotech Acquires US CRO NCGS, Expands Global Expertise

Singapore & Charlotte, NC, May 5, 2022 – (ACN Newswire) – Novotech, the leading Asia-Pacific biotech specialist CRO, has acquired US CRO NCGS as part of its expansion program, and can now offer its biotech clients clinical services in the US to support later phase global studies. NCGS, established in 1984 in South Carolina, is a privately held CRO with a biopharma client base and a workforce of about 300 professionals across the US.

Novotech CEO Dr. John Moller said "We are very pleased to acquire such an impressive company with a strong history of quality and delivery in the United States. The company's growth is a real credit to the knowledge and expertise of founder Nancy Snowden and the exceptional team she has formed.

"This is a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs. Clients will receive seamless service, with a unified approach to systems and SOPs well developed," Moller said.

Nancy C.G. Snowden, founder and CEO of NCGS, said the company was excited about becoming part of Novotech operations globally and supporting Novotech's clients with their US clinical programs. "We have a similar cultural fit and focus on excellence, so joining Novotech will be seamless for both ours and Novotech's clients. Novotech and NCGS have a collaboration history of over a decade which will also support the seamless integration," said Snowden.

"NCGS focuses on complex areas of clinical development; oncology, hematology, infectious disease, and CNS in both adult and pediatric populations. Our lean organizational structure and nimble operational model with highly tenured staff have been specifically designed to overcome the challenges inhibiting our industry today. We have the ability to pivot in real time as the needs of the trial evolve," Sowden said.

Novotech serves biotechs globally, leveraging deep relationships built with hundreds of Asia-Pacific sites over the last 25 years. NCGS compliments this with a broad US site base and hundreds of investigators with relationships spanning nearly four decades.

Media Contact:
David James
E: communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
ASIA: +65 3159 3427

About Novotech Health Holdings

Novotech Health Holdings Pte. Ltd. ("Novotech") is a leading Asia-Pacific biotech specialist CRO with integrated labs and phase I facilities providing drug development consulting and clinical development services. Novotech Holdings is well positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally. For further information, visit https://novotech-cro.com/.

About NCGS

NCGS Incorporated, founded in 1984, is a full-service CRO that specializes in conducting and managing clinical trials. NCGS has supported the development of more than 70 approved pharma-biotech, diagnostic and device products with over 80 indications during its nearly four decades of operation. For more information, please visit https://www.ncgs.com/sponsors/.

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Avantor Announces Investment in Manufacturing and Distribution Hub in Singapore to Serve Rapidly Growing Asia Pacific Biopharma Industry

Singapore, May 5, 2022 – (ACN Newswire) – Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, today announced it will create a new manufacturing and distribution Hub in Singapore, by integrating its existing distribution facility with new manufacturing operations. The new Hub, which brings Avantor solutions closer to regional customers and strengthens global supply chain capabilities, will be fully operational early next year.


Avantor announced it will create a new Manufacturing and Distribution Hub in Singapore by integrating its existing distribution facility with new manufacturing operations.


"The Singapore Manufacturing and Distribution Hub will enable Avantor to better serve the fast-growing Asia Pacific Biopharma market by facilitating shorter lead times, enhancing supply chain security and increasing capacity in the region," said Christophe Couturier, Executive Vice President, AMEA, Avantor. "The Hub will boost regional innovation and serve as an industry benchmark for Singapore and Asia Pacific's global quality and regulatory standards, and demonstrates Avantor's commitment to growing our presence in the region."

The new Hub will provide a range of services including quality control and inventory management expertise, and feature cGMP manufacturing suites and testing labs for process ingredients and excipients.

About Avantor

Avantor, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world.

For more information, visit https://news.avantorsciences.com/home and find us on:
LinkedIn: https://www.linkedin.com/company/avantorinc/
Twitter: https://twitter.com/Avantor_News
Facebook: https://www.facebook.com/Avantorinc/

Regional Media Contact
Christina Koh
Director, Communications – AMEA
Avantor
M: +65 9720 0169
Christina.Koh@avantorsciences.com

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

The Executive Talk by ShareInvestor: Thonburi Healthcare Group PCL (SET: THG)

BANGKOK, May 2, 2022 – (ACN Newswire) – Thonburi Healthcare Group PCL (SET: THG) Chief Executive Officer, Dr. Tanatip Suppradit (M.D.) discusses the business performance during the Covid-19 pandemic, and the economic outlook in 2022.

1. What opportunities did you see from the Covid-19 crisis? And how has the Thonburi Healthcare Group managed to handle the situation?

It was a crisis, but the crisis is a lesson, as many of you have seen that THG worked very hard. Last year felt like a 10-year work. Over 6-7 thousand, all the employees worked hard all day and night. And the result was satisfactory. Just vaccination alone is hundreds of thousands of people. Not to mention the medical treatment and field hospital where we provided 4-5 thousand beds during the Delta wave. During the Omicron, we are still active today. After the Songkran festival, the case might double. But we must do it because this is our duty. Our occupation is medical treatment and making Thai people safe and disease-free.

2. What was the key to success that makes the turnover of THG business performance in 2021?

For the key to success, we are a group of hospitals that help the government and civil society work on Covid-19. Therefore, the key to success is the desire to help protect people from the disease. Next is the personnel. Thank you very much. I talked to many about those new generation doctors and nurses. They fought for life. They are white-robed heroes who are devoted to others. In terms of operating results last year, we did a lot, so we gained a lot. It reflected that any hospitals that provided medical care related to Covid-19 would get good results. But whoever did not do it might lose since ordinary people did not get sick as much. Flu, and diarrhea, are all gone because everyone's hygienics are very good. Wearing a mask makes it almost impossible to catch a cold. Last year I didn't have a cold at all. But for hospitals that offer tertiary care, such as cancer surgery, brain surgery, and heart surgery, the groups of people with serious diseases still exist.

3. What's the goal for 2022?

In the picture of the first half, the situation is probably the same as the 2-3rd quarter of last year since there are still omicrons. Despite people getting sick, they are more careful. However, will any new Corvids be coming in the 3rd quarter of this year? No one can answer. Supposed if there were no, then it would gradually fade. Instead, it will be a matter of other diseases, which we must adjust as follows. Common conditions such as flu and diarrhea may not occur as much because people are still very good hygienic. The challenge is the loss of purchasing power due to the economy. So, entrepreneurs must adjust how they survive.

4. To what extent have you implemented the innovation related to digital technology?

We are in the era of global technology transformation from Web 2 to Web 3, where we see telemedicine and home medicine delivery. Therefore, everything integrates between healthcare, technology, and human behavior. Suppose the elderly can't use it, I have an initiative that we will apply technology to Gen Y, but the patient is elderly. It will bring a combination of Generation and Technology. So, Gen Y is not sick, but they are the elderly helpers. We have recently started developing the digital platform, which we expect to launch within 1-2 months. This platform will simplify access to hospital services. Easier and more accurate. It's an interesting year as several things are changing. It occurs in two dimensions at the same time. On the one hand, the resource side, which the doctor and nurse have adjusted. On the other hand, is the patient's side. Covid-19 has forced every stakeholder to adapt to find a mutual point.

5. Today we are at Jin Wellbeing County. Can you tell us more about this project?

Jin is a prototype project that we aim to make a new standard for the country. The idea started about 7-8 years ago. It took us three years to build, and we finally finished about three and a half years ago. Gradually, householders were coming in, both the elderly and bedridden patients – those in need of a caretaker. Supposed not enough care at home, just stay here. Living here, the elderly will never feel trapped in a confined room. You don't have to be afraid that you will fall somewhere, or it will be dangerous. A whole community featured a well-designed landscape, surrounded by the hospital's CCTV network. And every room has a few alarms, both by the bed and in the bathroom, like hospital standards. When they twitched, a team of doctors and nurses would immediately rush to rescue them.

Most importantly, there is also a master key that the doctor can tap and get into the room. The most apparent difference between a hospital and a home is that the rooms are lockable and non-lockable. At Jin, it's a combination of a house and a hospital. Therefore, people have two options. If they have a lot of treasure and don't want to be disturbed, that's okay. Just make it like an ordinary condo. However, despite a lot of glory in the room, you think that life is more vital, then you sign consent for us to hold the master key. Whenever there was an emergency alarm, we perceived you as a patient in a hospital ward.

6. What do you see as the major threats these days?

This year, I point to three main issues. First is the economy. What to do in an economic situation where the purchasing power of a whole country is gone? Will medical tourism come back? They will come for sure, but how soon?

The second is how the Covid goes. Looking at the graph, we suppose the Omicron is at its peak; it's been two years and four months. Usually, according to biology, it runs like a bell shape. Not that tomorrow or next quarter it will disappear or go extinct. It will gradually fade within another year or two. At the same time, people's behavior will change as they get used to it. Thus, the epidemic is another challenge.

Third, Multi-Generation and Technology, which is the transition of Webs. From Web 2, which we have been using for 15 years, to Web 3. They call it the "Scarcity of digitization." Before, we contributed digital activities independently. Now it is scarcity like NFT and so on. This change, to some extent, will match healthcare as the scarcity of digitization makes it unique. Healthcare service, such as a patient consulting with a doctor, is one-on-one, not one-on-many. Therefore, if Web 3 technology is unique and private, it will maintain the one-on-one service.

Consequently, there will be more healthcare services on the Web 3 platform. Personally, I believe that the "scarcity of digitization" principle will continue to be the birthplace of essential healthcare on Web 3 and will bring about a genuinely viable service. The information base will be more individual. It also includes the issue of safety of practice. As a result, medical procedures will be safer for practitioners like me and the patients. In addition, they will contribute more "Trust" on Web 3.

7. What core values do you and your employees adhere to at work?

The main principle of THG is, first of all, quality and standard. And based on ethics. We must adhere to this. In the end, the business rewards will follow. We perceive healthcare as planting a perennial plant. We are planting trees that are hundreds of years old. Some of them might grow a bit slow. That's fine. We see this as the core value. The ambiance surrounding, such as Aging society, Digital platforms, products like hemp and marijuana, or Wellness, are just add-ons. In the end, the core is medical treatment.

About The Executive Q&A Series

The Executive Q&A Series is presented by ShareInvestor, Asia's leading financial internet media and technology company and the largest investor relations network in the region. For more information, email admin.th@shareinvestor.com. Website: www.ShareInvestorThailand.com

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Malaysian Genomics Resource Centre Berhad Supports Yayasan Seri Negara’s Ramadhan Initiative

PETALING JAYA, Malaysia, Apr 28, 2022 – (ACN Newswire) – Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to support Yayasan Seri Negara's (YSN) Ihya Ramadhan 2022 programme through a monetary donation to help those in need.


Dato' Seri Mazlan Lazim, Patron of Yayasan Seri Negara and Encik Azri Azerai, Executive Director of Malaysian Genomics Resource Centre [L-R]


The Ihya Ramadhan 2022 programme will be held in several locations throughout the country and involves the breaking of fast and the giving of monetary aid to orphans and the underprivileged.

Encik Azri Azerai, Executive Director of Malaysian Genomics, said, "We are happy and honoured to be able to assist YSN in their Ihya Ramadhan 2022 programme. Every little bit helps, and we want to do our part in easing the burden of those in need such as orphans and the underprivileged."

Malaysian Genomics' cash aid will be distributed to orphans and the underprivileged at the Shah Alam district police headquarters during the Ihya Ramadhan 2022 programme held at the location on 27 April 2022 at 6pm.

Malaysian Genomics Resource Centre Berhad: http://www.mgrc.com.my/
Malaysian Genomics Resource Centre Berhad: 0155 / [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK]

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

World Malaria Day 2022, Vestergaard CEO: Advance Equity. Build Resilience. End Malaria.

LAUSANNE, Switzerland, Apr 25, 2022 – (ACN Newswire) – World Malaria Day provides us with a moment to reflect on the scale of the challenge we still face – and recognise what needs to happen to fix it.


When a community is equipped with effective insecticidal bed nets, it not only protects the individual family, but it also reduces the vector population in that community. [Vestergaard]


Make no mistake, great strides have been made. El Salvador and China were certified malaria free in 2021. However, most countries with a high burden of the disease have suffered setback and are losing ground.

How can we be satisfied, when 627,000 people died in 2021, from what is a curable disease? More than two thirds of those deaths were among children under the age of 5 living in the African Region.

This human tragedy, devastating millions of families, is impossible to comprehend. But the socio-economic impact however is calculable, and it is immense.

The global response to the COVID crisis proved that when the global economy is threatened, we can summon the power to overcome a disease which emerged almost overnight. So, why can't we solve, rather than manage, a curable disease that we have lived with for far too long?

Simply, it requires us to strain every sinew in our collective global health-body, to move in the same direction, at scale.

So, what is stopping us?

We have tackled the low hanging fruit. The strategy and tactics we employed to get us this far will not serve to meet the WHO goal to reduce, by 90%, the global malaria incidence and mortality rates by 2030.

The WHO has clearly stated that it will require new approaches and greatly intensified efforts, aided by new tools and the better implementation of existing ones. Stepped-up investment is also essential.

So how is that going to happen?

The WHO, working with its partners, has done a fantastic job, figuring out how to marshal billions of dollars in unified ways, to a deliver an agreed strategy. It has developed one regulatory framework across a multitude of countries and eliminated masses of bureaucracy. Even though incident rates may not have reduced, death rates have reduced a lot. That means patients are being diagnosed quicker, treated quicker and treated successfully.

It doesn't change the reality, though. The disease remains resilient and concentrated in a specific group of countries. We face many headwinds – climate change, vector resistance to the early class of insecticides, to name two. We need innovation to get ahead of these trends.

And despite the introduction of new interventions such as vaccines and seasonal malaria chemoprevention, mosquito nets will remain a core intervention to save lives until elimination.

Three hundred million people sleep under Vestergaard bed nets every night. What motivates us, is we can see direct relationship between our product and saving lives.

The bed net, probably, is the most cost-effective public health device that ever existed.

When a community is equipped with effective insecticidal bed nets, it not only protects the individual family, but it also acts to decimate the vector population in that community.

The goal of achieving universal coverage, however, has limits, because of the need to adapt the mix of tools deployed for maximum impact in diverse settings. It is a funding challenge – how do we achieve universal coverage while introducing more effective and therefore costly mosquito nets, while at the same time expanding the number of nets to keep pace with population growth?

It is also a logistical challenge: are mass campaign distributions, every 2-3 years, the best method to ensure equitable access for the populations that need it most?

We now need all actors to work together to establish something that has so far eluded us – strategic supply collaboration; a partnership approach to planning, procurement and distribution of mosquito nets.

There is a good reason why every industry, from automotive, to pharma, has moved in this direction. It drives long term investment, accelerates innovation, delivers efficiency – and indeed, can deliver lower unit costs.

A singular focus on price reduction, does not incentivize capital investment and innovation. Conversely, long-term, strategic relationships build resilience of the supply chain, another lesson we learned from COVID.

The reality is, we cannot perform to our full potential in the current environment. Timescales (1-3 years of contract) are too short.

We must also recognize that the private sector in the arena is not homogenous – there are large corporations who contribute chemistry, mostly as a CSR initiative; opportunistic cost-driven suppliers – and ones like ourselves who are full innovation partners.

The leading private sector organizations are ready to invest, automate and innovate to reduce cost.

Vestergaard is uniquely positioned to deliver this innovation at scale because we have constantly challenged ourselves to go further to save lives. We began by simply dipping nets in insecticide to increase protection, through to the development of PermaNet(R) 2.0, the first long lasting insecticidal net (LLIN) to be deployed at scale in the early 2000's. However, the disease does not stand still. Fast spreading mosquito resistance to pyrethroids demanded a response. Vestergaard led the successful large-scale deployment of piperonyl butoxide long-lasting insecticidal nets (PBO LLINs), specifically designed to protect against pyrethroid-resistant mosquitoes.

We will introduce our first dual active-ingredient net, PermaNet(R) Dual in the second half of 2022. The product will help serve a growing demand for dual AI nets.

However, sustaining innovation requires a strategic partnership with the customer – in this case, the funders. Beyond the New Nets Project, they need to define a new model to accelerate innovation and establish long term engagement with innovative suppliers with the goal to bring new nets to market in way that supports equitable access.

So, what would I like to see happen before World Malaria Day 2023?

Fundamentally, that we stop managing the disease and pull together to end malaria.

Michael Joos
CEO, Vestergaard

Contact:
Ayomide Ibironke
Tel: +27 61 326 4765
Africa Communications Media Group
ayomide@africacommunicationsgroup.com

View the article in English: https://tinyurl.com/vestergaard-20220422-en
View the article in French: https://tinyurl.com/vestergaard-20220422-fr

This Op Ed is issued through EmailWire.Com (www.emailwire.com) – the global newswire service that provides Press Release distribution with guaranteed results(TM).

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

World Malaria Day 2022 – Vestergaard CEO: Advance Equity. Build Resilience. End Malaria.

LAUSANNE, Switzerland, Apr 25, 2022 – (ACN Newswire)World Malaria Day provides us with a moment to reflect on the scale of the challenge we still face – and recognise what needs to happen to fix it.

Make no mistake, great strides have been made. El Salvador and China were certified malaria free in 2021. However, most countries with a high burden of the disease have suffered setback and are losing ground.

How can we be satisfied, when 627,000 people died in 2021, from what is a curable disease? More than two thirds of those deaths were among children under the age of 5 living in the African Region.

This human tragedy, devastating millions of families, is impossible to comprehend. But the socio-economic impact however is calculable, and it is immense.

The global response to the COVID crisis proved that when the global economy is threatened, we can summon the power to overcome a disease which emerged almost overnight. So, why can’t we solve, rather than manage, a curable disease that we have lived with for far too long?

Simply, it requires us to strain every sinew in our collective global health-body, to move in the same direction, at scale.

So, what is stopping us?

We have tackled the low hanging fruit. The strategy and tactics we employed to get us this far will not serve to meet the WHO goal to reduce, by 90%, the global malaria incidence and mortality rates by 2030.

The WHO has clearly stated that it will require new approaches and greatly intensified efforts, aided by new tools and the better implementation of existing ones. Stepped-up investment is also essential.

So how is that going to happen?

The WHO, working with its partners, has done a fantastic job, figuring out how to marshal billions of dollars in unified ways, to a deliver an agreed strategy. It has developed one regulatory framework across a multitude of countries and eliminated masses of bureaucracy. Even though incident rates may not have reduced, death rates have reduced a lot. That means patients are being diagnosed quicker, treated quicker and treated successfully.

It doesn’t change the reality, though. The disease remains resilient and concentrated in a specific group of countries. We face many headwinds – climate change, vector resistance to the early class of insecticides, to name two. We need innovation to get ahead of these trends.

And despite the introduction of new interventions such as vaccines and seasonal malaria chemoprevention, mosquito nets will remain a core intervention to save lives until elimination.

Three hundred million people sleep under Vestergaard bed nets every night. What motivates us, is we can see direct relationship between our product and saving lives.

The bed net, probably, is the most cost-effective public health device that ever existed.

When a community is equipped with effective insecticidal bed nets, it not only protects the individual family, but it also acts to decimate the vector population in that community.

The goal of achieving universal coverage, however, has limits, because of the need to adapt the mix of tools deployed for maximum impact in diverse settings. It is a funding challenge – how do we achieve universal coverage while introducing more effective and therefore costly mosquito nets, while at the same time expanding the number of nets to keep pace with population growth?

It is also a logistical challenge: are mass campaign distributions, every 2-3 years, the best method to ensure equitable access for the populations that need it most?

We now need all actors to work together to establish something that has so far eluded us – strategic supply collaboration; a partnership approach to planning, procurement and distribution of mosquito nets.

There is a good reason why every industry, from automotive, to pharma, has moved in this direction. It drives long term investment, accelerates innovation, delivers efficiency – and indeed, can deliver lower unit costs.

A singular focus on price reduction, does not incentivize capital investment and innovation. Conversely, long-term, strategic relationships build resilience of the supply chain, another lesson we learned from COVID.

The reality is, we cannot perform to our full potential in the current environment. Timescales (1-3 years of contract) are too short.

We must also recognize that the private sector in the arena is not homogenous – there are large corporations who contribute chemistry, mostly as a CSR initiative; opportunistic cost-driven suppliers – and ones like ourselves who are full innovation partners.

The leading private sector organizations are ready to invest, automate and innovate to reduce cost.

Vestergaard is uniquely positioned to deliver this innovation at scale because we have constantly challenged ourselves to go further to save lives. We began by simply dipping nets in insecticide to increase protection, through to the development of PermaNet® 2.0, the first long lasting insecticidal net (LLIN) to be deployed at scale in the early 2000’s. However, the disease does not stand still. Fast spreading mosquito resistance to pyrethroids demanded a response. Vestergaard led the successful large-scale deployment of piperonyl butoxide long-lasting insecticidal nets (PBO LLINs), specifically designed to protect against pyrethroid-resistant mosquitoes.

We will introduce our first dual active-ingredient net, PermaNet® Dual in the second half of 2022. The product will help serve a growing demand for dual AI nets.

However, sustaining innovation requires a strategic partnership with the customer – in this case, the funders. Beyond the New Nets Project, they need to define a new model to accelerate innovation and establish long term engagement with innovative suppliers with the goal to bring new nets to market in way that supports equitable access.

So, what would I like to see happen before World Malaria Day 2023?

Fundamentally, that we stop managing the disease and pull together to end malaria.

Michael Joos
CEO, Vestergaard
www.vestergaard.com

View the article in English: https://tinyurl.com/vestergaard-20220422-en
View the article in French: https://tinyurl.com/vestergaard-20220422-fr

Contact:
Ayomide Ibironke
Tel: +27 61 326 4765
Africa Communications Media Group
ayomide@africacommunicationsgroup.com

This Op Ed is issued through EmailWire.Com (www.emailwire.com) – the global newswire service that provides Press Release distribution with guaranteed results™.



Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com